 Braxia Scientific Corp. CSE:BRAX, OTC:BRAXF Braxia Scientific Corp. CSE:BRAX, OTC:BRAXF, Braxia Scientific Corp. CSE:BRAX, OTC:BRAXF has announced its results for the first quarter of fiscal 2023 with an increase in the number of treatments driving a 13 quarter-on-quarter rise in revenue. The medical research and telemedicine company, which provides ketamine and psilocybin treatments for depression and related disorders, also said it launched KetaMD in the US, increasing access to treatment for mental health patients. 